Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAUT: Nilotinib Re-treatment and Second Stop in CML
NCT02917720Phase 2Active, not recruiting
- Sponsor
- European LeukemiaNet
- Start
- Sep 2016
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myeloid leukemia (CML), sponsored by European LeukemiaNet. Primary endpoint: Duration of Major Molecular Response or better. Started Sep 2016; status: active, not recruiting.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02917720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917720.